ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 2022, the Board of Directors established a Special Committ...
GlobeNewswire · 05/05 20:15
ARCA biopharma GAAP EPS of -$0.23
ARCA biopharma press release (NASDAQ:ABIO): Q1 GAAP EPS of -$0.23. Cash and cash equivalents were $49.1 million as of March 31, 2022, compared to $53.4 million as of December 31,
Seekingalpha · 05/02 20:57
BRIEF-Arca Biopharma Announces First Quarter 2022 Financial Results · 05/02 20:53
-- Earnings Flash (ABIO) ARCA BIOPHARMA Reports Q1 Loss $-0.23
MT Newswires · 05/02 16:26
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million.
Benzinga · 04/18 21:34
BRIEF-Arca Biopharma Establishes Special Committee Of The Board Of Directors · 04/18 20:50
ARCA biopharma establishes special board committee to evaluate strategic options
ARCA biopharma (NASDAQ:ABIO) on Monday established a special committee of its board of directors to evaluate strategic options for the biopharmaceutical company. ABIO did not specify what kind of options
Seekingalpha · 04/18 20:44
ARCA biopharma Reports Has Established Special Committee Of Board
ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that its Board of Directors
Benzinga · 04/18 20:31
Arca Biopharma Board to Weigh Strategic Options for Company -- Shares Rise After-Hours
MT Newswires · 04/18 17:04
Albioma : Governance changes
Press release Paris La Défense, 5 April 2022 Governance changes Marie-Claire Daveu has informed Albioma today of her intention to resign from the Board of Directors with effect from 31 July 2022, with her appointment as Director to be submitted to Engie's ...
GlobeNewswire · 04/05 05:35
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Investor Place · 04/04 11:30
38 Stocks Moving In Friday's Mid-Day Session
Gainers Manning & Napier, Inc. (NYSE: MN) jumped 40.7% to $12.82 after the company reported it will be acquired by Callodine Group and will go private at $12.85 per share.
Benzinga · 04/01 16:56
Mid-Morning Market Update: Markets Higher; US Economy Adds 431,000 Jobs In March
U.S. stocks opened higher this morning following the release of non-farm payroll data for March.
Benzinga · 04/01 14:21
ORIC, Unity Biotechnology top healthcare gainers; SELLAS, Pulse Biosciences lead losers' pack
Gainers: ORIC Pharmaceuticals (ORIC) +14%. Unity Biotechnology (UBX) +13%. Applied Therapeutics (APLT) +11%. Genetron (GTH) +11%. Clarus Therapeutics (CRXT) +8%. Losers: SELLAS Life Sciences SLS -39%. Pulse Biosciences (PLSE) -22%. Spero Therapeutics SPRO ...
Seekingalpha · 04/01 14:00
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 04/01 13:11
The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 04/01 13:08
ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study
ARCA biopharma Inc (NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19.
Benzinga · 04/01 11:09
21 Stocks Moving in Friday's Pre-Market Session
Gainers Blackboxstocks Inc. (NASDAQ: BLBX) rose 37.6% to $3.69 in pre-market trading after the company reported better-than-expected Q4 sales results.
Benzinga · 04/01 11:09
BRIEF-ARCA Biopharma Reports Topline Results For Aspen-Covid-19 Phase 2B Clinical Trial · 03/31 21:16
Arca biopharma fails to meet key goal in mid-stage trial for COVID-19 therapy
Arca Biopharma (NASDAQ:ABIO) is trading ~28% lower in the post-market Thursday after the clinical-stage biotech announced that its experimental COVID-19 therapy rNAPc2 failed to meet the primary endpoint with statistical significance in
Seekingalpha · 03/31 20:42
Webull provides a variety of real-time ABIO stock news. You can receive the latest news about Arca Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABIO
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is focused on development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product includes Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) and Gencaro(bucindolol hydrochloride). rNAPc2 (AB201) is a treatment for diseases caused by ribonucleic acid (RNA), viruses, focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus. Gencaro(bucindolol hydrochloride) is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties for the treatment of atrial fibrillation (AF) in patients with heart failure. AF is the form of cardiac arrhythmia, a disruption of the heart’s normal rhythm or rate. The Company is conducting Phase II b clinical trial of rNAPc2 (AB201), ASPEN-COVID-19. It is also conducting Phase IIB/III clinical trial of Gencaro.